| Published Application/Species/Sample/Dilution | Reference |
|---|
- flow cytometry; human; loading ...; fig 3b
| Lavoie R, Gargollo P, Ahmed M, Kim Y, Baer E, Phelps D, et al. Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion. Cancers (Basel). 2021;13: pubmed publisher |
- flow cytometry; human; 1:200; loading ...; fig s7f
| Wu S, Xiao Y, Wei J, Xu X, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9: pubmed publisher |
- flow cytometry; human; loading ...; fig 5b, 5d, e4f
| Mendoza J, Escalante N, Jude K, Sotolongo Bellon J, Su L, Horton T, et al. Structure of the IFNγ receptor complex guides design of biased agonists. Nature. 2019;567:56-60 pubmed publisher |
- flow cytometry; human; 1:300; loading ...; fig s1b
| Geng Y, Liu X, Liang J, Habiel D, Kulur V, Coelho A, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019;4: pubmed publisher |
- flow cytometry; human; loading ...; fig 1c
| Richardson J, Armbruster N, Günter M, Henes J, Autenrieth S. Staphylococcus aureus PSM Peptides Modulate Human Monocyte-Derived Dendritic Cells to Prime Regulatory T Cells. Front Immunol. 2018;9:2603 pubmed publisher |
- flow cytometry; human; fig 2c
| Lundell A, Nordström I, Andersson K, Lundqvist C, Telemo E, Nava S, et al. IFN type I and II induce BAFF secretion from human decidual stromal cells. Sci Rep. 2017;7:39904 pubmed publisher |
- flow cytometry; human; 1:100; fig 5a
| Beatson R, Tajadura Ortega V, Achkova D, Picco G, Tsourouktsoglou T, Klausing S, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17:1273-1281 pubmed publisher |
- flow cytometry; human; fig s6b
| Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher |
- flow cytometry; human; 1:40; fig 1
| Zhang J, Wang C, Zhang P, Wang X, Chen J, Yang J, et al. Expression of programmed death 1 ligand 1 on periodontal tissue cells as a possible protective feedback mechanism against periodontal tissue destruction. Mol Med Rep. 2016;13:2423-30 pubmed publisher |
| Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed publisher |
| Taylor J, Bulek A, Gannon I, Robson M, Kokalaki E, Grothier T, et al. Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2. Front Immunol. 2023;14:1119350 pubmed publisher |
| Gu T, Tian X, Wang Y, Yang W, Li W, Song M, et al. Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint. Front Immunol. 2023;14:1145028 pubmed publisher |
| Hu X, White K, Olroyd A, Dejesus R, Dominguez A, Dowdle W, et al. Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat Biotechnol. 2023;: pubmed publisher |
| Lafor xea ts F, Kotantaki P, Malacrida B, Elorbany S, Manchanda R, Donnadieu E, et al. Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments. iScience. 2023;26:106514 pubmed publisher |
| Yang A, Zhang Z, Chaurasiya S, Park A, Jung A, Lu J, et al. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases. J Immunother Cancer. 2023;11: pubmed publisher |
| Yi X, Wang H, Yang Y, Wang H, Zhang H, Guo S, et al. SIRT7 orchestrates melanoma progression by simultaneously promoting cell survival and immune evasion via UPR activation. Signal Transduct Target Ther. 2023;8:107 pubmed publisher |
| Li D, Qin J, Zhou T, Li Y, Cheng X, Chen Z, et al. Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC. Int J Oncol. 2023;62: pubmed publisher |
| Wu Y, Zhou L, Zou Y, Zhang Y, Zhang M, Xu L, et al. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity. Nat Cancer. 2023;4:382-400 pubmed publisher |
| Fox D, Ebright R, Hong X, Russell H, Guo H, LaSalle T, et al. Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. NPJ Precis Oncol. 2023;7:25 pubmed publisher |
| Hajibabaei S, Sotoodehnejadnematalahi F, Nafissi N, Zeinali S, Azizi M. Aberrant promoter hypermethylation of miR-335 and miR-145 is involved in breast cancer PD-L1 overexpression. Sci Rep. 2023;13:1003 pubmed publisher |
| Chen L, Liu S, Adah D, Sun Q, Liang Z, Ho M, et al. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma. Immunology. 2023;169:204-218 pubmed publisher |
| He Y, Zhang X, Zhu M, He W, Hua H, Ye F, et al. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. J Transl Med. 2023;21:25 pubmed publisher |
| Herter J, Kiljan M, Kunze S, Reinscheid M, Ibruli O, Cai J, et al. Influence of chemoradiation on the immune microenvironment of cervical cancer patients. Strahlenther Onkol. 2023;199:121-130 pubmed publisher |
| Li C, Park H, Shin J, Baik J, Mehrara B, Kataru R. Tumor-Associated Lymphatics Upregulate MHC-II to Suppress Tumor-Infiltrating Lymphocytes. Int J Mol Sci. 2022;23: pubmed publisher |
| Zhang Z, Ji W, Huang J, Zhang Y, Zhou Y, Zhang J, et al. Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients. Clin Transl Med. 2022;12:e1072 pubmed publisher |
| Lau P, Zhang G, Zhao S, Liang L, Zhang H, Zhou G, et al. Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. Cell Mol Immunol. 2022;19:1153-1167 pubmed publisher |
| Rydyznski Moderbacher C, Kim C, Mateus J, Plested J, Zhu M, Cloney Clark S, et al. NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses. J Clin Invest. 2022;132: pubmed publisher |
| Deepak H, Prince S, Deshpande P. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis. Indian J Pharmacol. 2022;54:183-193 pubmed publisher |
| Hu H, Xiang Y, Li T, Yu Q, Gu L, Liao X, et al. Induction of M-MDSCs with IL6/GM-CSF from adherence monocytes and inhibition by WP1066. Exp Ther Med. 2022;24:487 pubmed publisher |
| Lee J, Chen M, Chou K, Chao Y, Chen M, Tsai C. Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response. Lupus Sci Med. 2022;9: pubmed publisher |
| Pathania A, Prathipati P, Olwenyi O, Chava S, Smith O, Gupta S, et al. miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma. Mol Ther Oncolytics. 2022;25:308-329 pubmed publisher |
| Jarosch S, K xf6 hlen J, Wagner S, D Ippolito E, Busch D. ChipCytometry for multiplexed detection of protein and mRNA markers on human FFPE tissue samples. STAR Protoc. 2022;3:101374 pubmed publisher |
| Wang H, Liu G, Jin X, Song S, Chen S, Zhou P, et al. BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC. J Cancer. 2022;13:2126-2137 pubmed publisher |
| Guo Q, Malloy M, Roweth H, McAllister S, Italiano J, Battinelli E. Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro. Blood Adv. 2022;6:5668-5675 pubmed publisher |
| Rodda L, Morawski P, Pruner K, Fahning M, Howard C, Franko N, et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell. 2022;185:1588-1601.e14 pubmed publisher |
| Oreskovic E, Wheeler E, Mengwasser K, Fujimura E, Martin T, Tothova Z, et al. Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1. Proc Natl Acad Sci U S A. 2022;119: pubmed publisher |
| Cui J, Zhu Y, Liu X, Wang W, Jiang X, Xia Y, et al. Comprehensive analysis of N6-methyladenosine regulators with the tumor immune landscape and correlation between the insulin-like growth factor 2 mRNA-binding protein 3 and programmed death ligand 1 in bladder cancer. Cancer Cell Int. 2022;22:72 pubmed publisher |
| Zhang W, Zhong W, Wang B, Yang J, Yang J, Yu Z, et al. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. Dev Cell. 2022;57:329-343.e7 pubmed publisher |
| Wang J, Xu Y, Rao X, Zhang R, Tang J, Zhang D, et al. BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer. Clin Transl Med. 2022;12:e718 pubmed publisher |
| Bouleau A, Nozach H, Dubois S, Kereselidze D, Chevaleyre C, WANG C, et al. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats. J Nucl Med. 2022;63:1259-1265 pubmed publisher |
| Zhang H, Xie W, Zhang Y, Dong X, Liu C, Yi J, et al. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. Cancer Gene Ther. 2022;29:456-465 pubmed publisher |
| Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, et al. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. J Nucl Med. 2022;63:536-542 pubmed publisher |
| Zhang Z, Yang A, Chaurasiya S, Park A, Lu J, Kim S, et al. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Ther. 2022;29:722-733 pubmed publisher |
| Jarosch S, K xf6 hlen J, Sarker R, Steiger K, Janssen K, Christians A, et al. Multiplexed imaging and automated signal quantification in formalin-fixed paraffin-embedded tissues by ChipCytometry. Cell Rep Methods. 2021;1:100104 pubmed publisher |
| El Ahanidi H, El Azzouzi M, Hafidi Alaoui C, Tetou M, Bensaid M, Chaoui I, et al. Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer. Front Oncol. 2021;11:795242 pubmed publisher |
| Yi K, Cui X, Liu X, Wang Y, Zhao J, Yang S, et al. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma. Front Immunol. 2021;12:802795 pubmed publisher |
| Leonard N, Reidy E, Thompson K, McDermott E, Peerani E, Tomas Bort E, et al. Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon Cancer. Cancers (Basel). 2021;13: pubmed publisher |
| Shen C, Zhang Z, Tian Y, Li F, Zhou L, Jiang W, et al. Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway. BMC Med. 2021;19:283 pubmed publisher |
| Darga E, Dolce E, Fang F, Kidwell K, Gersch C, Kregel S, et al. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS ONE. 2021;16:e0260124 pubmed publisher |
| Liang Y, Chen K, Tsai J, Cheng Y, Lee C, Kao C, et al. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. J Biomed Sci. 2021;28:75 pubmed publisher |
| Houtsma R, Hogeling S, Schuringa J. CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones. STAR Protoc. 2021;2:100864 pubmed publisher |
| Ahn A, Rodger E, Motwani J, Gimenez G, Stockwell P, Parry M, et al. Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling Pathways. Cancers (Basel). 2021;13: pubmed publisher |
| Curnock A, Bossi G, Kumaran J, Bawden L, Figueiredo R, Tawar R, et al. Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI Insight. 2021;6: pubmed publisher |
| Tsuchiya K, Yoshimura K, Inoue Y, Iwashita Y, Yamada H, Kawase A, et al. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer. Oncoimmunology. 2021;10:1962656 pubmed publisher |
| Kenty J, Pelayo G, Leite N. Retrieval and purification of human β cells from stem cell-derived islet engrafted mice. STAR Protoc. 2021;2:100675 pubmed publisher |
| Geuijen C, Tacken P, Wang L, Klooster R, Van Loo P, Zhou J, et al. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat Commun. 2021;12:4445 pubmed publisher |
| Shao L, He Q, Wang J, He F, Lin S, Wu L, et al. MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3. Cell Death Discov. 2021;7:145 pubmed publisher |
| Yoshino H, Sato Y, Nakano M. KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1. Curr Issues Mol Biol. 2021;43:153-162 pubmed publisher |
| Wang Y, Gu T, Tian X, Li W, Zhao R, Yang W, et al. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Front Immunol. 2021;12:654463 pubmed publisher |
| Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S, et al. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression. Adv Sci (Weinh). 2021;8:2003404 pubmed publisher |
| Dai X, Bu X, Gao Y, Guo J, Hu J, Jiang C, et al. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell. 2021;81:2317-2331.e6 pubmed publisher |
| Hu Q, Li H, Archibong E, Chen Q, Ruan H, Ahn S, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng. 2021;5:1038-1047 pubmed publisher |
| Wu Y, Zhang C, Liu X, He Z, Shan B, Zeng Q, et al. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. Nat Commun. 2021;12:2346 pubmed publisher |
| Fujiwara Y, Tsunedomi R, Yoshimura K, Matsukuma S, Fujiwara N, Nishiyama M, et al. Pancreatic Cancer Stem-Like Cells With High Calreticulin Expression Associated With Immune Surveillance. Pancreas. 2021;50:405-413 pubmed publisher |
| Zhang R, Xu T, Xia Y, Wang Z, Li X, Chen W. ITM2A as a Tumor Suppressor and Its Correlation With PD-L1 in Breast Cancer. Front Oncol. 2020;10:581733 pubmed publisher |
| Liu Y, Li X, Zhang H, Zhang M, Wei Y. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer. Oncogene. 2021;40:2230-2242 pubmed publisher |
| Soday L, Potts M, Hunter L, Ravenhill B, Houghton J, Williamson J, et al. Comparative Cell Surface Proteomic Analysis of the Primary Human T Cell and Monocyte Responses to Type I Interferon. Front Immunol. 2021;12:600056 pubmed publisher |
| Roberts A, Bentley L, Tang T, Stewart F, Pallini C, Juvvanapudi J, et al. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation. Sci Rep. 2021;11:4030 pubmed publisher |
| Li H, Kuang X, Liang L, Ye Y, Zhang Y, Li J, et al. The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1. Adv Sci (Weinh). 2021;8:2001596 pubmed publisher |
| Okita R, Shimizu K, Nojima Y, Saisho S, Nakata M. Tofacitinib overcomes an IFNγ-induced decrease in NK cell-mediated cytotoxicity via the regulation of immune-related molecules in LC-2/ad. Thorac Cancer. 2021;12:775-782 pubmed publisher |
| Ye L, Peng W, Niu Y, Xiang X, Wei X, Wang Z, et al. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis. Ann Transl Med. 2020;8:1647 pubmed publisher |
| Lei Y, Zhang G, Zhang C, Xue L, Yang Z, Lü Z, et al. The average copy number variation (CNVA) of chromosome fragments is a potential surrogate for tumor mutational burden in predicting responses to immunotherapy in non-small-cell lung cancer. Clin Transl Immunology. 2021;10:e1231 pubmed publisher |
| Katsurahara K, Shiozaki A, Kosuga T, Shimizu H, Kudou M, Arita T, et al. ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer. Cancer Sci. 2021;112:1026-1037 pubmed publisher |
| Zhou C, Wei W, Ma J, Yang Y, Liang L, Zhang Y, et al. Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels. Mol Ther. 2021;29:1512-1528 pubmed publisher |
| Kwak T, Wang F, Deng H, Condamine T, Kumar V, Perego M, et al. Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. Cell Rep. 2020;33:108571 pubmed publisher |
| Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, et al. Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. Front Oncol. 2020;10:575737 pubmed publisher |
| Huang X, Williams J, Chang R, Li Z, Burnett C, Hernández López R, et al. DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation. Nat Nanotechnol. 2021;16:214-223 pubmed publisher |
| Park J, Cheung N. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. J Hematol Oncol. 2020;13:172 pubmed publisher |
| Rydyznski Moderbacher C, Ramirez S, Dan J, Grifoni A, Hastie K, Weiskopf D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020;183:996-1012.e19 pubmed publisher |
| Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, et al. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. Genome Med. 2020;12:83 pubmed publisher |
| Jiang G, Shi L, Zheng X, Zhang X, Wu K, Liu B, et al. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Aging (Albany NY). 2020;12:11466-11484 pubmed publisher |
| Mao R, Tan X, Xiao Y, Wang X, Wei Z, Wang J, et al. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells. Cancer Sci. 2020;111:3174-3183 pubmed publisher |
| Zhang C, Fan Y, Che X, Zhang M, Li Z, Li C, et al. Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28. Front Oncol. 2020;10:760 pubmed publisher |
| Mineo M, Lyons S, Zdioruk M, von Spreckelsen N, Ferrer Luna R, Ito H, et al. Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Mol Cell. 2020;78:1207-1223.e8 pubmed publisher |
| Gilardini Montani M, Falcinelli L, Santarelli R, Granato M, Romeo M, Cecere N, et al. KSHV infection skews macrophage polarisation towards M2-like/TAM and activates Ire1 α-XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expression. Br J Cancer. 2020;123:298-306 pubmed publisher |
| Fan Z, Tian Y, Chen Z, Liu L, Zhou Q, He J, et al. Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. EMBO Mol Med. 2020;12:e11571 pubmed publisher |
| Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, et al. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports. 2020;14:49-59 pubmed publisher |
| Ng K, Attig J, Young G, Ottina E, Papamichos S, Kotsianidis I, et al. Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. elife. 2019;8: pubmed publisher |
| Kumagai Y, Ohzawa H, Miyato H, Horie H, Hosoya Y, Lefor A, et al. Surgical Stress Increases Circulating Low-Density Neutrophils Which May Promote Tumor Recurrence. J Surg Res. 2020;246:52-61 pubmed publisher |
| Sugawara E, Kato M, Kudo Y, Lee W, Hisada R, Fujieda Y, et al. Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. Autophagy. 2020;16:946-955 pubmed publisher |
| Kim D, Kim H, Choi Y, Kim S, Lee J, Sung K, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med. 2019;51:94 pubmed publisher |
| Zong Z, Zou J, Mao R, Ma C, Li N, Wang J, et al. M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling. Front Immunol. 2019;10:1643 pubmed publisher |
| Bryson B, Rosebrock T, Tafesse F, Itoh C, Nibasumba A, Babunovic G, et al. Heterogeneous GM-CSF signaling in macrophages is associated with control of Mycobacterium tuberculosis. Nat Commun. 2019;10:2329 pubmed publisher |
| Iwasa M, Harada T, Oda A, Bat Erdene A, Teramachi J, Tenshin H, et al. PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ. Oncotarget. 2019;10:1903-1917 pubmed publisher |
| Souriant S, Balboa L, Dupont M, Pingris K, Kviatcovsky D, Cougoule C, et al. Tuberculosis Exacerbates HIV-1 Infection through IL-10/STAT3-Dependent Tunneling Nanotube Formation in Macrophages. Cell Rep. 2019;26:3586-3599.e7 pubmed publisher |
| Tsukamoto M, Imai K, Ishimoto T, Komohara Y, Yamashita Y, Nakagawa S, et al. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Cancer Sci. 2019;110:310-320 pubmed publisher |
| Su S, Zhao J, Xing Y, Zhang X, Liu J, Ouyang Q, et al. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell. 2018;175:442-457.e23 pubmed publisher |
| Zhao Y, Harrison D, Song Y, Ji J, Huang J, Hui E. Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Rep. 2018;24:379-390.e6 pubmed publisher |
| Lin J, Izar B, Wang S, Yapp C, Mei S, Shah P, et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. elife. 2018;7: pubmed publisher |
| Rolfes V, Idel C, Pries R, Plötze Martin K, Habermann J, Gemoll T, et al. PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget. 2018;9:27460-27470 pubmed publisher |
| Wu L, Liu H, Guo H, Wu Q, Yu S, Qin Y, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients. Oncol Lett. 2018;15:9507-9515 pubmed publisher |
| Kagoya Y, Nakatsugawa M, Saso K, Guo T, Anczurowski M, Wang C, et al. DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models. Nat Commun. 2018;9:1915 pubmed publisher |
| Tran L, Allen C, Xiao R, Moore E, Davis R, Park S, et al. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. Cancer Immunol Res. 2017;5:1141-1151 pubmed publisher |
| Schott D, Pizon M, Pachmann U, Pachmann K. Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors. Oncotarget. 2017;8:72755-72772 pubmed publisher |
| Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, et al. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8:15440 pubmed publisher |
| Guan H, Wan Y, Lan J, Wang Q, Wang Z, Li Y, et al. PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer. Sci Rep. 2016;6:35651 pubmed publisher |
| Rosskopf S, Jutz S, Neunkirchner A, Candia M, Jahn Schmid B, Bohle B, et al. Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens. Sci Rep. 2016;6:31580 pubmed publisher |
| Dan J, Lindestam Arlehamn C, Weiskopf D, da Silva Antunes R, Havenar Daughton C, Reiss S, et al. A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood. J Immunol. 2016;197:983-93 pubmed publisher |
| Jutz S, Leitner J, Schmetterer K, Doel Perez I, Majdic O, Grabmeier Pfistershammer K, et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1. J Immunol Methods. 2016;430:10-20 pubmed publisher |
| Maute R, Gordon S, Mayer A, McCracken M, Natarajan A, Ring N, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A. 2015;112:E6506-14 pubmed publisher |
| Nduom E, Wei J, Yaghi N, Huang N, Kong L, Gabrusiewicz K, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18:195-205 pubmed publisher |
| Padet L, Loubaki L, Bazin R. Induction of PD-L1 on monocytes: a new mechanism by which IVIg inhibits mixed lymphocyte reactions. Immunobiology. 2014;219:687-94 pubmed publisher |
| Durand Panteix S, Farhat M, Youlyouz Marfak I, Rouaud P, Ouk Martin C, David A, et al. B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. J Immunol. 2012;189:181-90 pubmed publisher |
| Lei J, Hasegawa H, Matsumoto T, Yasukawa M. Peroxisome proliferator-activated receptor ? and ? agonists together with TGF-? convert human CD4+CD25- T cells into functional Foxp3+ regulatory T cells. J Immunol. 2010;185:7186-98 pubmed publisher |
